0362-5486 < 0362-5664 < 0363-6135

Facettes :

List of bibliographic references indexed by 0362-5664

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]

Ident.	Authors (with country if any)	Title
002F11 (2003)	Simon Lemay [Canada] ; Pierre Blanchet [Canada] ; Sylvain Chouinard [Canada] ; Hélène Masson [Canada] ; Valérie Soland [Canada] ; Marc-André Bedard [Canada]	Poor tolerability of a transdermal nicotine treatment in Parkinson's disease
003049 (2002)	Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada]	Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil
003098 (2002)	Nicole Duchesne [Canada] ; Jean-Paul Soucy [Canada] ; Hélène Masson [Canada] ; Sylvain Chouinard [Canada] ; Marc-André Bedard [Canada]	Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients on and OFF levodopa
003301 (2001)	Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis]	Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study
003345 (2001)	Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte	Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
003355 (2001)	Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada]	Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis
003551 (2000)	D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada]	The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease
003557 (2000)	ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada]	Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys
003827 (1999)	V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada]	Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys
003A51 (1998)	M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France]	Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist
004085 (1995)	A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada]	Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis
004097 (1995)	P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY	Dopamine-receptor families and the treatment of Parkinson's disease. Discussion
004125 (1994)	D B Calne [Canada]	Early idiopathic parkinsonism: initiation and optimization of treatment.
004826 (1991)	B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard	Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism
004849 (1990)	R. Quirion [Canada] ; I. Aubert ; Y. Robitaille ; S. Gauthier ; D M Araujo ; J G Chabot	Neurochemical deficits in pathological brain aging: specificity and possible relevance for treatment strategies.
004852 (1990)	A H Rajput [Canada] ; B. Rozdilsky ; A. Rajput ; L. Ang	Levodopa efficacy and pathological basis of Parkinson syndrome.
004B38 (1989)	E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne	Clozapine: an antipsychotic agent in Parkinson's disease?
004C84 (1987)	H A Robertson [Canada] ; G S Robertson	Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action.
004D87 (1987)	A. E. Lang	Restless legs syndrome and Parkinson's disease: insights into pathophysiology
004D90 (1987)	H. A. Robertson ; G. S. Robertson	Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action
004E96 (1986)	C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne	Sinemet in Parkinson's disease: efficacy with and without food

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "0362-5664" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "0362-5664" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    0362-5664
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022